Improving kidney cancer treatment using a new vascular therapy
Vascular image-guided optimization of response (VIGOR) to therapy in kidney cancer
This study is looking at a new treatment for kidney cancer that targets the unusual blood vessels in tumors to help shrink them, and it aims to see how well this treatment works when used with other existing therapies, giving patients a potential new option to improve their care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project ID | NIH-10871855 on NIH RePORTER |
What this research studies
This research focuses on enhancing kidney cancer treatment by developing a novel vascular disrupting agent (VDA) that targets the abnormal blood vessels in tumors. The approach aims to disrupt the tumor's blood supply, leading to tumor cell death and improved outcomes when combined with existing therapies. Patients may benefit from a new treatment option that could work alongside current medications to better manage their condition. The study will involve testing the effectiveness of this agent in combination with other therapies to determine the best treatment strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with renal cell carcinoma who are seeking advanced treatment options.
Not a fit: Patients with kidney cancer who are not eligible for additional therapies or those with early-stage disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide kidney cancer patients with a more effective treatment option that enhances the efficacy of existing therapies.
How similar studies have performed: Previous research has shown promise in using vascular disrupting agents in cancer treatment, indicating potential for success with this novel approach.
Where this research is happening
Dallas, United States
- Ut Southwestern Medical Center — Dallas, United States (Active)
Researchers
- Principal investigator: Liu, Li — Ut Southwestern Medical Center
- Study coordinator: Liu, Li
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.